65 related articles for article (PubMed ID: 7911159)
1. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.
Francis PA; Rigas JR; Kris MG; Pisters KM; Orazem JP; Woolley KJ; Heelan RT
J Clin Oncol; 1994 Jun; 12(6):1232-7. PubMed ID: 7911159
[TBL] [Abstract][Full Text] [Related]
2. Different treatment efficacies and side effects of cytotoxic chemotherapy.
Li LJ; Chong Q; Wang L; Cher GB; Soo RA
J Thorac Dis; 2020 Jul; 12(7):3785-3795. PubMed ID: 32802458
[TBL] [Abstract][Full Text] [Related]
3. Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort.
Sone K; Oguri T; Uemura T; Takeuchi A; Fukuda S; Takakuwa O; Maeno K; Fukumitsu K; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
BMC Cancer; 2019 Mar; 19(1):246. PubMed ID: 30890141
[TBL] [Abstract][Full Text] [Related]
4. Safety of Polysorbate 80 in the Oncology Setting.
Schwartzberg LS; Navari RM
Adv Ther; 2018 Jun; 35(6):754-767. PubMed ID: 29796927
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: a meta-analysis of randomized clinical trials.
Li A; Wei ZJ; Ding H; Tang HS; Zhou HX; Yao X; Feng SQ
Oncotarget; 2017 Aug; 8(34):57365-57378. PubMed ID: 28915677
[TBL] [Abstract][Full Text] [Related]
6. Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer.
Chen Y; Li J; Chen S; Zhang Y; Hu Y; Zhang G; Yan X; Jiao S
Sci Rep; 2017 Sep; 7(1):10760. PubMed ID: 28883517
[TBL] [Abstract][Full Text] [Related]
7. Combination Chemotherapy with Docetaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer.
Schuette W; Bork I; Wollschläger B; Schädlich S
Clin Drug Investig; 2001 Mar; 21(3):161-8. PubMed ID: 27517545
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators.
Caiado J; Picard M
Curr Allergy Asthma Rep; 2014 Aug; 14(8):451. PubMed ID: 24951237
[TBL] [Abstract][Full Text] [Related]
9. Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review.
Picard M; Castells MC
Clin Rev Allergy Immunol; 2015 Oct; 49(2):177-91. PubMed ID: 24740483
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.
Yano R; Konno A; Watanabe K; Tsukamoto H; Kayano Y; Ohnaka H; Goto N; Nakamura T; Masada M
Int J Clin Oncol; 2013 Feb; 18(1):96-104. PubMed ID: 22095245
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of docetaxel and ifosfamide for patients with platinum-resistant or refractory non-small cell lung cancer in a salvage setting.
Lee GW; Kang JH; Kim SH; Lee HY; Kim HC; Lee WS; Lee JD; Hwang YS; Jang JS; Lee JS
Cancer Res Treat; 2004 Oct; 36(5):287-92. PubMed ID: 20368817
[TBL] [Abstract][Full Text] [Related]
12. A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer results of a Japan Clinical Oncology Group trial (JCOG 0204).
Kunitoh H; Kato H; Tsuboi M; Asamura H; Tada H; Nagai K; Mitsudomi T; Koike T; Nakagawa K; Ichinose Y; Okada M; Shibata T; Saijo N;
Br J Cancer; 2008 Sep; 99(6):852-7. PubMed ID: 18728643
[TBL] [Abstract][Full Text] [Related]
13. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.
Lin SH; Lee YC; Choueiri MB; Wen S; Mathew P; Ye X; Do KA; Navone NM; Kim J; Tu SM; Yu-Lee LY; Logothetis CJ
Clin Cancer Res; 2008 Jun; 14(12):3729-36. PubMed ID: 18559590
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of docetaxel and carboplatin as a first-line therapy in patients with stage IV non-small-cell lung cancer.
Kataoka K; Suzuki R; Taniguchi H; Noda Y; Shindoh J; Matsumoto S; Watanabe Y; Honda K; Suzuki K; Baba K; Imaizumi K; Kume H; Hasegawa Y; Takagi K
Lung; 2006; 184(3):133-9. PubMed ID: 16902837
[TBL] [Abstract][Full Text] [Related]
15. Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer.
Han JY; Hong EK; Lee SY; Yoon SM; Lee DH; Lee JS
J Clin Pathol; 2005 Jun; 58(6):650-4. PubMed ID: 15917420
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer: results of a phase II study.
Firvida JL; Amenedo M; Rodríguez R; González A; Salgado M; Ramos M; Losada G
Invest New Drugs; 2004 Nov; 22(4):481-7. PubMed ID: 15292719
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC).
Israel V; Tagawa ST; Snyder T; Jeffers S; Raghavan D
Invest New Drugs; 2004 Aug; 22(3):291-7. PubMed ID: 15122076
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
Masters GA; Brockstein BE; Mani S; Ratain MJ
Med Oncol; 2003; 20(1):7-12. PubMed ID: 12665678
[TBL] [Abstract][Full Text] [Related]
19. The role of new agents in advanced non-small-cell lung carcinoma.
Langer CJ
Curr Oncol Rep; 2000 Jan; 2(1):76-89. PubMed ID: 11122828
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel: a review of its use in non-small cell lung cancer.
Comer AM; Goa KL
Drugs Aging; 2000 Jul; 17(1):53-80. PubMed ID: 10933515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
